Related Experiment Video
Updated: Dec 8, 2025
08:01
Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
Published on: November 30, 2022
5.3K
Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives
Sabine Wessels1,2, Thomas Muley2,3, Petros Christopoulos1,2
1Department of Thoracic Oncology, Thoraxklinik at University Hospital Heidelberg, D-69126 Heidelberg, Germany.
Translational Lung Cancer Research
|September 21, 2020
Summary
Prospective collection of cryopreserved tumor biopsies and blood samples in advanced non-small-cell lung cancer (NSCLC) is feasible. This serial biomaterial acquisition supports personalized patient management and translational research for novel therapies.
Area of Science:
- Oncology
- Translational Research
- Biomaterial Science
Background:
- Tumor material availability is crucial for managing non-small-cell lung cancer (NSCLC), particularly for targeted therapies and immune checkpoint inhibitors.
- Prospective biomaterial acquisition in advanced NSCLC is essential for personalized medicine and research.
Purpose of the Study:
- To assess the feasibility of longitudinal, high-quality biomaterial acquisition in advanced non-small-cell lung cancer (NSCLC) patients.
- To collect cryopreserved biopsies, FFPE biopsies, blood samples, and clinical data for research and patient management.
Main Methods:
- Longitudinal collection of cryopreserved and FFPE biopsies, blood samples (serum, plasma, buffy-coat), and clinical data over five years.
- Standardized questionnaires for detailed clinical annotation.
- Biopsy procedures included forceps biopsy and cryobiopsy; tissue quality assessed by cellularity, DNA/RNA yield, and RNA integrity (RIN).
Main Results:
- 205 patients enrolled, yielding 387 cryopreserved biopsies and 1,098 blood samples.
- Feasibility of cryopreserved biopsy acquisition was 89% at diagnosis, decreasing to 56% and 47% at first and second progression.
- Cryobiopsy yielded higher tissue amounts; biopsies had median 34% tumor cellularity, 13.6 µg DNA, and 12 µg RNA (median RIN=8).
- Up to 38 blood samples per patient were collected across multiple therapy lines.
Conclusions:
- Serial biomaterial acquisition, including cryopreserved biopsies, is feasible in advanced NSCLC patients, supporting individualized management.
- Standardized collection of high-quality biomaterials facilitates translational research, advancing therapeutic options for NSCLC.
